Farragut Webinar | 2021 Outlook for Value-Based Care and the Self-Insured Employer Marketplace
Mar 2021
On Thursday, March 18, 2021, Lincoln International’s Barry Freeman and Michael Siano joined Farragut Square Group’s webinar, to discuss why we are seeing so many deals among value-based care (VBC)-focused providers and the self-insured employer market. Our experts from the firm’s Healthcare Group, along with fellow presenters from Stax Inc, address:
- What VBC means in practice
- Trends in self-insured landscape development and employer adoption of VBC
- Sectors most relevant to the self-insured employer market and the valuations deals are trading for
- Categories of strategic buyers currently operating in this sector and opportunities for PE investors
- Why the market environment is fertile for these types of companies
- The role and influence of CMS and private payers in driving progress on VBC
Please complete the form below to access to this recording:
Summary
-
On Thursday, March 18, 2021, experts from Lincoln International's Healthcare Group joined Farragut Square Group's webinar to discuss value-based care and the self-insured employer market.
- Sign up to receive Lincoln's perspectives
Contributors
Meet Professionals with Complementary Expertise
I enjoy working closely with clients to overcome challenging situations and to develop strategies to meet their business goals.
Dirk-Oliver Löffler
Managing Director | European Co-head Healthcare
Frankfurt
Related Perspectives
PETS International | Consolidation Meets Regulation in the Veterinary Clinics Market
Originally posted by PETS International on April 5, 2024. Animal health is becoming a big business in Europe and the U.S. Thus, regulators are turning a closer eye to mergers… Read More
“Leader to Leader” Series
The Leader to Leader video series turns up the dial on rich conversations with prominent leaders – from business owners and entrepreneurs to investors and CEOs – highlighting their stories… Read More
What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access
The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More
Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal
The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More
